Lv1
40 积分 2026-01-05 加入
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug–Drug Interaction Predictions
11天前
已完结
Can a High-Dose of Furmonertinib Effectively Address Unmet Needs in EGFR-Mutated NSCLC with Leptomeningeal Metastases?
11天前
已完结
[Measurements of vancomycin concentrations in the blood - a method of personalization the antibiotic therapy in patients with chronic kidney disease]
21天前
已关闭
Vancomycin removal and pharmacokinetics during accelerated venovenous hemofiltration
21天前
已完结
Drug-induced enzyme activity inhibition and CYP3A4 genetic polymorphism significantly shape the metabolic characteristics of furmonertinib
27天前
已完结
Simultaneous determination of alflutinib and its active metabolite in human plasma using liquid chromatography–tandem mass spectrometry
1个月前
已完结
Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
1个月前
已完结
Evaluation of the pharmacokinetic effects of itraconazole on alflutinib (AST2818): an open-label, single-center, single-sequence, two-period randomized study in healthy volunteers
1个月前
已完结
[Chinese Medical Association guideline for clinical diagnosis and treatment of lung cancer (2024 edition)]
1个月前
已完结
Furmonertinib: First Approval
1个月前
已完结
皖公网安备34019202002308
